Is Nmn Safe

Safety of Nicotinamide Mononucleotide (NMN) Supplementation

Introduction to NMN and Its Benefits

Nicotinamide mononucleotide (NMN) is a precursor to nicotinamide adenine dinucleotide (NAD+), a crucial molecule involved in various metabolic processes, including energy production, DNA repair, and stress responses. NMN has gained attention for its potential anti-aging benefits and its ability to ameliorate age-related diseases .

Clinical Trials on NMN Safety in Humans

Oral Administration Studies

Several clinical trials have investigated the safety of NMN when administered orally. A placebo-controlled, randomized, double-blind study involving 30 healthy subjects demonstrated that a daily dose of 250 mg of NMN for 12 weeks did not cause any adverse effects. The study also showed a significant increase in NAD+ levels in the blood, suggesting that NMN is a safe and effective way to boost NAD+ levels in humans.

Another study involving 10 healthy Japanese men tested single doses of 100, 250, and 500 mg of NMN. The results indicated no significant clinical symptoms or changes in vital signs, except for minor fluctuations in serum bilirubin, creatinine, chloride, and blood glucose levels, all within normal ranges. This study further confirmed the safety of NMN in humans.

A larger study with 66 middle-aged and older adults also supported these findings. Participants who took 300 mg of NMN daily for 60 days showed increased NAD+ levels without any significant adverse effects, reinforcing the safety profile of NMN.

Intravenous Administration Studies

In addition to oral administration, the safety of intravenous NMN has also been evaluated. A study involving 10 healthy volunteers found that intravenous NMN administration did not affect electrocardiograms, pulse, blood pressure, or metabolic markers in vital organs. The study also noted significant increases in blood NAD+ levels, indicating that intravenous NMN is safe and beneficial .

Preclinical Safety Evaluations

Animal Studies

Preclinical studies in animals have provided additional safety data. In Sprague-Dawley rats, high doses of NMN (up to 2666 mg/kg) did not result in any mortality or adverse effects. A 90-day sub-chronic study with doses up to 1500 mg/kg/day also showed no toxic effects, establishing a No-Observable Adverse Effect Level (NOAEL) for NMN.

Similarly, studies in mice and beagle dogs demonstrated that NMN is well-tolerated even at high doses, with only minor increases in certain biomarkers, which were not clinically significant.

Conclusion

The collective evidence from human clinical trials and preclinical animal studies strongly suggests that NMN is safe for both oral and intravenous administration. NMN supplementation effectively increases NAD+ levels without causing significant adverse effects, making it a promising candidate for mitigating age-related disorders and promoting overall health. However, ongoing and future clinical trials are essential to further validate these findings and establish long-term safety profiles.

Summary

Consensus Meter

Safety of Nicotinamide Mononucleotide (NMN) Supplementation

Introduction to NMN and Its Benefits

Clinical Trials on NMN Safety in Humans

Oral Administration Studies

Intravenous Administration Studies

Preclinical Safety Evaluations

Animal Studies

Conclusion

Sources and full results

Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects

Safety evaluation after acute and sub-chronic oral administration of high purity Nicotinamide mononucleotide (NMN-C®) in Sprague-Dawley rats.

Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men.

Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns

Subacute Toxicity Study of Nicotinamide Mononucleotide via Oral Administration

MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-aged and Older Adults.

A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults

Intravenous Uptake of NMN is Safely Metabolize and Increases NAD+ Levels in Healthy Subjects

Nicotinamide Mononucleotide Is Safely Metabolized and Significantly Reduces Blood Triglyceride Levels in Healthy Individuals

Yeast Cell Surface Engineering of a Nicotinamide Riboside Kinase for the Production of β-Nicotinamide Mononucleotide via Whole-Cell Catalysis.

Try another search